Large B cell lymphoma-year by year

ABSTRACT

Non Hodgkin's Lymphoma [NHL] comprises a group of lymphoproliferative disorders the frequency of which continues to rise. Although many classification systems exist for identifying specific histological subtypes, NHL is generally divided into indolent [low-grade] and aggressive [intermediate- and high-grade] forms. Large B Cell Lymphoma [LBCL] is one of the commonest aggressive NHLs. The aim of this review is to provide a general overview of NHL, its clinically practicable cellular classification, epidemiology and in depth overview of the evolution of treatment of LBCL during the past 5 years. Current guidelines from National Cancer Institute [NCI], USA and National Institute on Clinical Excellence [NICE], UK are mentioned and recommendations according to our own set-up are suggested